Huma-Zolamide (Acetazolamide)

Huma‑Zolamide (acetazolamide) is prescribed for several conditions where reduction of fluid production is therapeutic.

• Management of elevated intra‑ocular pressure in primary open‑angle glaucoma and secondary glaucomas.
• Adjunctive therapy for certain seizure disorders, particularly when other antiepileptic drugs are insufficient.
• Prophylaxis and early treatment of acute mountain sickness in individuals ascending to high altitude.
• Treatment of idiopathic intracranial hypertension to lower cerebrospinal fluid production.
• Short‑term use for reduction of fluid overload in specific metabolic alkalosis or diuretic‑resistant states.

• Acetazolamide, the active component of Huma‑Zolamide, reversibly inhibits the enzyme carbonic anhydrase in the ciliary body of the eye and in renal tubular cells. By blocking the conversion of carbon dioxide and water to bicarbonate, it decreases bicarbonate reabsorption, leading to reduced aqueous humor formation and increased urinary excretion of bicarbonate, sodium, and water. This enzymatic inhibition underlies its antiglaucoma and diuretic effects.

Like other carbonic anhydrase inhibitors, Huma‑Zolamide may be associated with a range of adverse reactions, most of which are mild and reversible.

Common

• Tingling or numbness in the fingers and toes (paresthesia).
• Altered taste, especially a metallic sensation.
• Increased urination and mild dehydration.
• Nausea, vomiting, or loss of appetite.
• Transient visual disturbances such as blurred vision.

Serious

• Severe electrolyte disturbances, including low potassium or sodium.
• Metabolic acidosis with rapid breathing.
• Allergic reactions such as rash, itching, or swelling of the face.
• Persistent kidney stones or renal impairment.
• Blood disorders like aplastic anemia or leukopenia.

Before initiating Huma‑Zolamide, clinicians should evaluate several patient‑specific factors to minimize risk.

• Assess renal function; dose adjustment may be required in impairment.
• Review electrolyte status, especially potassium and sodium levels.
• Use cautiously in patients with chronic obstructive pulmonary disease or other conditions predisposing to metabolic acidosis.
• Avoid in individuals with known hypersensitivity to sulfonamide drugs.
• Monitor for signs of hepatic dysfunction during prolonged therapy.
• Consider pregnancy status; safety data are limited, and benefits must outweigh potential risks.
• Evaluate for concurrent use of other diuretics that may amplify fluid and electrolyte loss.

Acetazolamide can affect the pharmacokinetics or pharmacodynamics of several other medicines, so potential interactions should be reviewed.

Avoid

• Concurrent use with high‑dose salicylates, which may increase the risk of metabolic acidosis.
• Combination with other carbonic anhydrase inhibitors, leading to additive diuretic effects.
• Co‑administration with drugs that heavily rely on renal excretion, such as certain aminoglycosides, may enhance nephrotoxicity.

Use with caution

• Loop or thiazide diuretics, as combined therapy can cause significant electrolyte disturbances.
• Antiepileptic drugs like phenytoin, where acetazolamide may alter serum levels.
• Carbonic anhydrase‑inhibiting agents used for glaucoma, requiring dose adjustments.
• Oral anticoagulants, because changes in plasma pH may affect clotting factor activity.